Millennium Management
UBX

Millennium Management’s Unity Biotechnology UBX Stock Holding History

Millennium Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,479
Closed -$14.1K – 6497
2024
Q2 		$14.1K Sell
10,479
-27,233
-72% -$41.4K ﹤0.01% 5571
2024
Q1 		$61.8K Buy
37,712
+24,274
+181% +$42.1K ﹤0.01% 5657
2023
Q4 		$25.9K Buy
+13,438
New +$25K ﹤0.01% 5595
2023
Q1 		– Sell
-16,546
Closed -$45K – 6882
2022
Q4 		$45K Sell
16,546
-82,933
-83% -$241K ﹤0.01% 5812
2022
Q3 		$393K Buy
99,479
+66,367
+200% +$419K ﹤0.01% 5157
2022
Q2 		$187K Sell
33,112
-42,104
-56% -$351K ﹤0.01% 5669
2022
Q1 		$842K Buy
75,216
+20,025
+36% +$225K ﹤0.01% 4690
2021
Q4 		$806K Buy
55,191
+11,260
+26% +$246K ﹤0.01% 4617
2021
Q3 		$1.32M Sell
43,931
-16,673
-28% -$588K ﹤0.01% 4380
2021
Q2 		$2.81M Buy
+60,604
New +$2.92M ﹤0.01% 3521
2020
Q3 		– Sell
-53,205
Closed -$4.62M – 4836
2020
Q2 		$4.62M Buy
53,205
+50,128
+1,629% +$3.72M 0.01% 1839
2020
Q1 		$178K Sell
3,077
-36,857
-92% -$2.32M ﹤0.01% 3428
2019
Q4 		$2.88M Buy
39,934
+18,667
+88% +$1.32M ﹤0.01% 2374
2019
Q3 		$1.3M Buy
21,267
+18,496
+667% +$1.31M ﹤0.01% 2703
2019
Q2 		$263K Sell
2,771
-5,771
-68% -$491K ﹤0.01% 3608
2019
Q1 		$693K Buy
+8,542
New +$969K ﹤0.01% 3072
2018
Q4 		– Sell
-4,090
Closed -$666K – 4187
2018
Q3 		$666K Buy
+4,090
New +$673K ﹤0.01% 3087

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

Millennium Management's UBX Position: Q3 2024 in Review

Millennium Management sold out of Unity Biotechnology (UBX) in Q3 2024, closing a stake of 10,479 shares — an estimated $14.1K sold.

Millennium Management first reported a position in UBX in Q3 2018 and held it in 17 quarters. The position peaked at $4.62M in Q2 2020. 38 funds tracked by Wall St. Rank hold UBX as of Q3 2024.

  • Millennium Management reported no remaining Unity Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Millennium Management sold 10,479 Unity Biotechnology shares in Q3 2024, an estimated $14.1K.
  • Millennium Management first reported a position in Unity Biotechnology in Q3 2018 and held it in 17 quarters.
  • Millennium Management's Unity Biotechnology position peaked at $4.62M in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2024.

Based on Millennium Management's 13F filing for Q3 2024, filed 14 Nov 2024.